Zobrazeno 1 - 10
of 170
pro vyhledávání: '"Saiama N. Waqar"'
Autor:
Nicholas P. Semenkovich, Shahed N. Badiyan, Pamela P. Samson, Hayley B. Stowe, Yun E. Wang, Rachel Star, Siddhartha Devarakonda, Ramaswamy Govindan, Saiama N. Waqar, Clifford G. Robinson, Gregory Vlacich, Bruna Pellini, Aadel A. Chaudhuri
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-6 (2023)
Abstract The optimal treatment paradigm for patients with oligometastatic non-small cell lung cancer (NSCLC) remains unclear. Some patients with oligometastatic disease experience prolonged remission after locally consolidative radiation therapy (RT)
Externí odkaz:
https://doaj.org/article/a58b67760151450588de5ad5ca91d57a
Autor:
Aaron S. Mansfield, David S. Hong, Christine L. Hann, Anna F. Farago, Himisha Beltran, Saiama N. Waqar, Andrew E. Hendifar, Lowell B. Anthony, Matthew H. Taylor, Alan H. Bryce, Scott T. Tagawa, Karl Lewis, Jiaxin Niu, Christine H. Chung, James M. Cleary, Michael Rossi, Carrianne Ludwig, Ricardo Valenzuela, Yan Luo, Rahul Aggarwal
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-7 (2021)
Abstract Delta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas/neuroendocrine tumors (NEC/NET). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Patients with NECs and other
Externí odkaz:
https://doaj.org/article/41cea5032a0d44ac9ceef9a9bed44b7a
Autor:
Brendan Knapp, Laura Mezquita, Siddhartha Devarakonda, Mihaela Aldea, Saiama N. Waqar, Kym Pepin, Jeffrey P. Ward, Angela Botticella, Karen Howarth, Charlene Knape, Clive Morris, Ramaswamy Govindan, Benjamin Besse, Daniel Morgensztern
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionCirculating tumor DNA (ctDNA) testing may identify patients at high risk for recurrence following chemoradiation (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC). We evaluated the feasibility of ctDNA testing on a readily
Externí odkaz:
https://doaj.org/article/bdec53ddcf914269b586e80415fd720d
Autor:
Alex H. Wagner, Siddhartha Devarakonda, Zachary L. Skidmore, Kilannin Krysiak, Avinash Ramu, Lee Trani, Jason Kunisaki, Ashiq Masood, Saiama N. Waqar, Nicholas C. Spies, Daniel Morgensztern, Jason Waligorski, Jennifer Ponce, Robert S. Fulton, Leonard B. Maggi, Jason D. Weber, Mark A. Watson, Christopher J. O’Conor, Jon H. Ritter, Rachelle R. Olsen, Haixia Cheng, Anandaroop Mukhopadhyay, Ismail Can, Melissa H. Cessna, Trudy G. Oliver, Elaine R. Mardis, Richard K. Wilson, Malachi Griffith, Obi L. Griffith, Ramaswamy Govindan
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Small cell lung cancer (SCLC) patients frequently relapse and become resistant to chemotherapy. Here, the authors analyse the genomic and transcriptomic landscape of primary and relapsed SCLC patients as well as in vitro models, and discover that act
Externí odkaz:
https://doaj.org/article/633460ab94c74c7ba9529694b90819e7
Autor:
Daniel Morgensztern, Daniel Boffa, Alexander Chen, Andrew Dhanasopon, Sarah B. Goldberg, Roy H. Decker, Siddhartha Devarakonda, Jane P. Ko, Luisa M. Solis Soto, Saiama N. Waqar, Ignacio I. Wistuba, Roy S. Herbst
Publikováno v:
Holland‐Frei Cancer Medicine. :1-29
Autor:
Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Katherine Minichiello, Liza C. Villaruz, Bryan Faller, Tareq Al Baghdadi, Susan Hines, Leah Everhart, Louise Highleyman, Vassiliki Papadimitrakopoulou, Joel W. Neal, Saiama N. Waqar, Jyoti D. Patel, Jhanelle E. Gray, David R. Gandara, Karen Kelly, Roy S. Herbst
Publikováno v:
J Clin Oncol
PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular endothelial growth factor (VEGF)/VEGF receptor inhibition has yielded promising resul
Autor:
Robert C. Doebele, Alice T. Shaw, Richard B. Lanman, Kurtis D. Davies, Dara L. Aisner, William T. Purcell, Saiama N. Waqar, Joseph Diaz, Christine E. Lee, Anh T. Le, Victoria M. Raymond, Ben M. Chue, Benjamin Levy, Kimberly C. Banks, Collin M. Blakely, Caroline E. McCoach
Supplementary Figures 1,2, 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71f38d61c5fa2e8747122d6aec6577ff
https://doi.org/10.1158/1078-0432.22464351
https://doi.org/10.1158/1078-0432.22464351
Autor:
David J. Kwiatkowski, Paul A. Bunn, Mark G. Kris, John D. Minna, Bruce E. Johnson, Ignacio I. Wistuba, Kelly Kugler, Yu Shyr, Julie Brahmer, Lecia V. Sequist, Saiama N. Waqar, Joan Schiller, Edward B. Garon, Jeremy Cetnar, Bonnie Glisson, Katerina Politi, Eric Haura, Gregory A. Otterson, Liza C. Villaruz, Suresh S. Ramalingam, Andre L. Moreira, Junya Fujimoto, Heidi Chen, Michael R. Rossi, Lynne D. Berry, Lynette M. Sholl, Dara L. Aisner
Supplemental Table 7: Cases with two or more oncogenic driver alterations. Supplemental Table 8. Comparison of LCMC I and LCMC II.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::220c9bfb87c6e273b0091ae22c15ae02
https://doi.org/10.1158/1078-0432.22465377
https://doi.org/10.1158/1078-0432.22465377
Autor:
Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
Supplemental Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54b6a5679d59d795489c267075719ba7
https://doi.org/10.1158/1078-0432.22464939
https://doi.org/10.1158/1078-0432.22464939
Autor:
Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
Supplemental Figure 1. Representative example from one patient showing the rash that was most frequently observed with ensartinib. The white arrow in the top figure points to the rash that is circled in the bottom figure.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f66975726db644fb04183f8f0be7ce6
https://doi.org/10.1158/1078-0432.22464948
https://doi.org/10.1158/1078-0432.22464948